Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• HIV Patients 100%
• Subclinical Atherosclerosis 100%
• Atorvastatin 100%
• CMV Seropositivity 100%
• Carotid Intima-media Thickness (cIMT) 75%
• Immune Activation 75%
• Statins 50%
• Non-communicable Diseases 25%
• Universitas Indonesia 25%
• Placebo 25%
• Informed Consent Form 25%
• HIV Infection 25%
• Cardiovascular Risk 25%
• Nave 25%
• Beneficial Effects 25%
• Thickness Measurement 25%
• Liver Fibrosis 25%
• Ethical Approval 25%
• Double-blind Placebo-controlled Trial 25%
• Ethics 25%
• Peer-reviewed Journals 25%
• Non-AIDS Comorbidities 25%
• Thickness Change 25%
• Fasting Triglycerides 25%
• Care Unit 25%
• Health Research Ethics 25%
• Integrated Care 25%
• Trial Results 25%
• Liver Steatosis 25%
• LDL-C Level 25%
• Community Periodontal Index 25%
• CMV Infection 25%
• Flow-mediated Vasodilation 25%
• Immune Inflammation 25%
• Statin-naïve 25%
• Neurocognitive Testing 25%

Medicine and Dentistry

• Human Immunodeficiency Virus 100%
• Placebo 100%
• Atherosclerosis 100%
• Atorvastatin 100%
• Intima-Media Thickness 50%
• Statin 50%
• Biological Marker 16%
• Non Communicable Disease 16%
• Informed Consent 16%
• Human Immunodeficiency Virus Infection 16%
• Cardiovascular Risk 16%
• Liver Fibrosis 16%
• Lifespan 16%
• Vasodilatation 16%
• Cytomegalovirus Infection 16%
• Fatty Liver 16%
• Periodontal Index 16%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Placebo 100%
• Atherosclerosis 100%
• Atorvastatin 100%
• Statin (Protein) 50%
• Biological Marker 16%
• Non Communicable Disease 16%
• Inflammation 16%
• Human Immunodeficiency Virus Infection 16%
• Cardiovascular Risk 16%
• Liver Fibrosis 16%
• Fatty Liver 16%
• Cytomegalovirus Infection 16%